false
0001468929
0001468929
2026-04-22
2026-04-22
0001468929
NXGL:CommonStockParValue0.001Member
2026-04-22
2026-04-22
0001468929
NXGL:WarrantsToPurchaseCommonStockMember
2026-04-22
2026-04-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 22, 2026
| NEXGEL,
INC. |
| (Exact
name of registrant as specified in its charter) |
| Delaware |
|
001-41173 |
|
26-4042544 |
| (State
or other jurisdiction |
|
(Commission
|
|
(IRS
Employer |
| of
incorporation) |
|
File Number) |
|
Identification
No.) |
2150
Cabot Boulevard West, Suite B
Langhorne,
Pennsylvania |
|
19047 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (215) 702-8550
(Former
name or former address, if changed since last report)
Not
Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 |
|
NXGL |
|
The
Nasdaq Capital Market LLC |
| Warrants
to Purchase Common Stock |
|
NXGLW |
|
The
Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
April 22, 2026, NexGel, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications
Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the
Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the
minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common
stock, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol “NXGL” at this time.
In
accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been given 180 calendar days, or until October 19, 2026, to regain
compliance with the Minimum Bid Price Requirement. If at any time before October 19, 2026, the bid price of the Company’s common
stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Staff will provide written confirmation that
the Company has achieved compliance.
If
the Company does not regain compliance with the Minimum Bid Price Requirement by October 19, 2026, the Company may be afforded a second
180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for
market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the Minimum Bid
Price Requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the deficiency during the second
compliance period, by effecting a reverse stock split if necessary. If the Company does not regain compliance with the Minimum Bid Price
Requirement by the end of the compliance period (or the second compliance period, if applicable), the Company’s common stock will
become subject to delisting. In the event that the Company receives notice that its common stock is being delisted, the Nasdaq listing
rules permit the Company to appeal a delisting determination by the Staff to a hearings panel.
The
Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance
with the Minimum Bid Price Requirement, including initiating a reverse stock split. However, there can be no assurance that the Company
will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing
Rules.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date:
April 24, 2026 |
|
|
| |
|
|
|
| |
|
NEXGEL,
INC. |
| |
|
|
|
| |
|
By: |
/s/
Adam Levy |
| |
|
|
Adam
Levy |
| |
|
|
Chief
Executive Officer |